Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

Equity Capital Markets

<ul><li>December 17, 2025 — Medline Industries, Inc. (NASDAQ: MDLN) began trading today on the Nasdaq Global Select Market following the pricing of its initial public offering at $29.00 per share.</li><li>Shares opened at $35.00 in their first public trade, representing an immediate gain of approximately 21 percent, and continued to build momentum throughout the session.</li><li>By the close, the stock finished near $41.00, delivering a first-day increase of roughly forty percent and marking one of the most consequential IPO debuts of 2025.</li></ul>

December 17, 2025 — Medline Industries, Inc. (NASDAQ: MDLN) began trading today on the Nasdaq Global Select Market following the pricing of its initial public offering at $29.00 per share.Shares opened at $35.00 in their first public trade, representing an immediate gain of approximately 21 percent, and continued to build momentum throughout the session.By the close, the stock finished near $41.00, delivering a first-day increase of roughly forty percent and marking one of the most consequential IPO debuts of 2025.

Medline Returns to Public Markets in Landmark IPO Debut

US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

<ul>
<li>Medline delivered a blockbuster debut, surging over 40% from issue to close, marking the largest and strongest IPO performance of 2025.</li>
<li>An upsized, heavily oversubscribed offering and powerful aftermarket trading signal deep institutional conviction and durable demand.</li>
<li>The deal positions Medline as a flagship IPO and a momentum-setting springboard for investor confidence heading into 2026.</li>
</ul>


Medline delivered a blockbuster debut, surging over 40% from issue to close, marking the largest and strongest IPO performance of 2025.
An upsized, heavily oversubscribed offering and powerful aftermarket trading signal deep institutional conviction and durable demand.
The deal positions Medline as a flagship IPO and a momentum-setting springboard for investor confidence heading into 2026.


Medline Inc. (MDLN): Blockbuster Debut Caps 2025 With a Statement Win

<ul>
<li>Medline’s IPO is poised to be 2025’s largest, with a potential $5.4bn raise, positioning it as a key bridge deal into the 2026 IPO pipeline.</li>
<li>Strong anchor demand and an oversubscribed book highlight investor appetite for scaled, mature healthcare platforms with durable cash flows.`</li>
<li>Proceeds will materially reduce leverage, supporting a more balanced capital structure and reinforcing Medline’s long-term investment appeal.</li>
</ul>


Medline’s IPO is poised to be 2025’s largest, with a potential $5.4bn raise, positioning it as a key bridge deal into the 2026 IPO pipeline.
Strong anchor demand and an oversubscribed book highlight investor appetite for scaled, mature healthcare platforms with durable cash flows.`
Proceeds will materially reduce leverage, supporting a more balanced capital structure and reinforcing Medline’s long-term investment appeal.


Medline Inc. (MDLN): Largest Cash Raise IPO Since 2021's Rivian Brings End of Year Opportunity

<ul><li>Medline Inc., the Northfield, Illinois–based medical products manufacturer and distributor, is advancing toward one of 2025’s largest IPOs.</li><li>The company plans to raise $5.0 billion by offering 179 million Class A shares at a price range of $26–$30, with an expected listing on the Nasdaq Global Select Market under the ticker MDLN.</li><li>At the midpoint valuation of $28, Medline would command a fully diluted market capitalization of approximately $37.3 billion, positioning it among the year’s most significant offerings.</li></ul>

Medline Inc., the Northfield, Illinois–based medical products manufacturer and distributor, is advancing toward one of 2025’s largest IPOs.The company plans to raise $5.0 billion by offering 179 million Class A shares at a price range of $26–$30, with an expected listing on the Nasdaq Global Select Market under the ticker MDLN.At the midpoint valuation of $28, Medline would command a fully diluted market capitalization of approximately $37.3 billion, positioning it among the year’s most significant offerings.

Medline Aims for a $5 Billion IPO as America’s Largest Privately Held Medical Supplier

<ul>
<li>Medline targets up to $5.4B in its IPO, the largest potential cash-raise since Rivian in 2021.</li>
<li>Strong anchor and cornerstone commitments signal deep institutional support ahead of one of the year’s most anticipated offerings.</li>
<li>Medline’s resilient, high-margin med-surg platform delivers consistent organic growth, reinforcing its profile as a mature, scaled issuer.</li>
</ul>


Medline targets up to $5.4B in its IPO, the largest potential cash-raise since Rivian in 2021.
Strong anchor and cornerstone commitments signal deep institutional support ahead of one of the year’s most anticipated offerings.
Medline’s resilient, high-margin med-surg platform delivers consistent organic growth, reinforcing its profile as a mature, scaled issuer.


Medline Inc. (MDLN): Hospital Product & Supply Chain Company Sets Terms on Mega IPO, $5b+ Cash Raise

United States

Medline Industries is a medical supply company, manufacturer and distributor.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Medline (MDLN US)

Medline Returns to Public Markets in Landmark IPO Debut

A strong first day of trading underscores renewed institutional demand for large, established healthcare issuers and signals a reopening of the...

IPO Prophet

Medline Inc. (MDLN): Blockbuster Debut Caps 2025 With a Statement Win

Medline's IPO soars over 40%, signaling strong institutional support and setting the stage for investor confidence in 2026.

IPO Boutique

Medline Inc. (MDLN): Largest Cash Raise IPO Since 2021's Rivian Brings End of Year Opportunity

Medline's upcoming IPO is set to be the largest of 2025, raising up to $5.4bn. Medline is a mature healthcare platforms with stable cash flows,...

IPO Boutique

Medline Aims for a $5 Billion IPO as America’s Largest Privately Held Medical Supplier

Backed by a century of family stewardship and a modern private-equity partnership, Medline is turning its integrated healthcare supply chain into...

IPO Prophet

Medline Inc. (MDLN): Hospital Product & Supply Chain Company Sets Terms on Mega IPO, $5b+ Cash Raise

Medline aims for $5.4B in IPO, backed by strong institutional support, with a proven track record of consistent organic growth.

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Medline Returns to Public Markets in Landmark IPO Debut

A strong first day of trading underscores renewed institutional demand for large, established healthcare issuers and signals a reopening of the...

IPO Prophet

Medline Inc. (MDLN): Blockbuster Debut Caps 2025 With a Statement Win

​Medline's IPO soars over 40%, signaling strong institutional support and setting the stage for investor confidence in 2026.

IPO Boutique

Medline Inc. (MDLN): Largest Cash Raise IPO Since 2021's Rivian Brings End of Year Opportunity

​Medline's upcoming IPO is set to be the largest of 2025, raising up to $5.4bn. Medline is a mature healthcare platforms with stable cash flows,...

IPO Boutique

Medline Aims for a $5 Billion IPO as America’s Largest Privately Held Medical Supplier

Backed by a century of family stewardship and a modern private-equity partnership, Medline is turning its integrated healthcare supply chain into...

IPO Prophet

Medline Inc. (MDLN): Hospital Product & Supply Chain Company Sets Terms on Mega IPO, $5b+ Cash Raise

​Medline aims for $5.4B in IPO, backed by strong institutional support, with a proven track record of consistent organic growth.

IPO Boutique

Medline's IPO soars over 40%, signaling strong institutional support and setting the stage for investor confidence in 2026.

Medline's upcoming IPO is set to be the largest of 2025, raising up to $5.4bn. Medline is a mature healthcare platforms with stable cash flows,...

Medline aims for $5.4B in IPO, backed by strong institutional support, with a proven track record of consistent organic growth.